{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:08Z","timestamp":1790916788178,"version":"4.1.0"},"reference-count":203,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":181,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018059","name":"Tanoto Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018059","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101312","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T05:30:52Z","timestamp":1783143052000},"page":"101312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Harnessing tumor-agnostic biomarkers for precision medicine in lymphoma"],"prefix":"10.1016","volume":"48","author":[{"given":"Yixuan","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole-Ann","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowena Lee Ying","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason Yongsheng","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2026.101312_bib0001","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.trecan.2020.08.009","article-title":"From tissue-agnostic to N-of-one therapies: (R)evolution of the precision paradigm","volume":"7","author":"Adashek","year":"2021","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101312_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.11.003","article-title":"If it is a solid tumor target, then it may be a hematologic cancer target: bridging the great divide","volume":"6","author":"Adashek","year":"2025","journal-title":"Med"},{"issue":"17","key":"10.1016\/j.ctarc.2026.101312_bib0003","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.ctarc.2026.101312_bib0004","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.ctarc.2026.101312_bib0005","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.3390\/cancers16142529","article-title":"Target-driven tissue-agnostic drug approvals-A new path of drug development","volume":"16","author":"Thein","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ctarc.2026.101312_bib0006","unstructured":"Research C for DE and. FDA grants accelerated approval to repotrectinib for adult and pediatric patients with NTRK gene fusion-positive solid tumors. FDA [Internet]. 2024 Jun 13 [cited 2025 May 17]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-repotrectinib-adult-and-pediatric-patients-ntrk-gene-fusion-positive."},{"key":"10.1016\/j.ctarc.2026.101312_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102721","article-title":"If it\u2019s a target, it\u2019s a pan-cancer target: tissue is not the issue","volume":"125","author":"Adashek","year":"2024","journal-title":"Cancer Treat. Rev."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101312_bib0008","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.21.02767","article-title":"Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion","volume":"40","author":"Chakravarty","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101312_bib0009","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO precision medicine working group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101312_bib0010","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101312_bib0011","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101312_bib0012","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/17474086.2017.1281122","article-title":"Lymphoma classification update: t-cell lymphomas, Hodgkin lymphomas, and histiocytic\/dendritic cell neoplasms","volume":"10","author":"Jiang","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.ctarc.2026.101312_bib0013","unstructured":"Research C for DE and. FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication. FDA [Internet]. 2024 Aug 9 [cited 2025 Jun 11]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication."},{"issue":"14","key":"10.1016\/j.ctarc.2026.101312_bib0014","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.3390\/cancers16142529","article-title":"Target-driven tissue-agnostic drug approvals\u2014a new path of drug development","volume":"16","author":"Thein","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ctarc.2026.101312_bib0015","unstructured":"Research C for DE and. FDA approves pembrolizumab for adults and children with TMB-H solid tumors. FDA [Internet]. 2024 Aug 9 [cited 2025 Jun 11]. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors."},{"key":"10.1016\/j.ctarc.2026.101312_bib0016","unstructured":"Research C for DE and. FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors. FDA [Internet]. 2024 Aug 9 [cited 2025 Jun 11]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors."},{"key":"10.1016\/j.ctarc.2026.101312_bib0017","unstructured":"Research C for DE and. FDA approves larotrectinib for solid tumors with NTRK gene fusions. FDA [Internet]. 2023 Sep 7 [cited 2025 Jun 11]. Available from: https:\/\/www.fda.gov\/drugs\/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions-0."},{"key":"10.1016\/j.ctarc.2026.101312_bib0018","unstructured":"Research C for DE and. FDA expands pediatric indication for entrectinib and approves new pellet formulation. FDA [Internet]. 2024 Aug 9 [cited 2025 Jun 11]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-pediatric-indication-entrectinib-and-approves-new-pellet-formulation."},{"key":"10.1016\/j.ctarc.2026.101312_bib0019","unstructured":"Research C for DE and. FDA grants accelerated approval to repotrectinib for adult and pediatric patients with NTRK gene fusion-positive solid tumors. FDA [Internet]. 2024 Jun 13 [cited 2025 Jun 11]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-repotrectinib-adult-and-pediatric-patients-ntrk-gene-fusion-positive."},{"key":"10.1016\/j.ctarc.2026.101312_bib0020","unstructured":"Research C for DE and. FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation. FDA [Internet]. 2024 Aug 9 [cited 2025 Jun 11]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid."},{"key":"10.1016\/j.ctarc.2026.101312_bib0021","unstructured":"Research C for DE and. FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors. FDA [Internet]. 2024 Aug 9 [cited 2025 Jun 11]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-solid-tumors."},{"key":"10.1016\/j.ctarc.2026.101312_bib0022","unstructured":"Research C for DE and. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. FDA [Internet]. 2024 Aug 9 [cited 2025 Jun 11]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2."},{"key":"10.1016\/j.ctarc.2026.101312_bib0023","unstructured":"Research C for DE and. FDA approves pemigatinib for relapsed or refractory myeloid\/lymphoid neoplasms with FGFR1 rearrangement. FDA [Internet]. 2024 Aug 9 [cited 2025 Jun 11]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pemigatinib-relapsed-or-refractory-myeloidlymphoid-neoplasms-fgfr1-rearrangement."},{"key":"10.1016\/j.ctarc.2026.101312_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.amsu.2022.103893","article-title":"A review of NTRK fusions in cancer","volume":"79","author":"Manea","year":"2022","journal-title":"Ann. Med. Surg."},{"issue":"Suppl 8","key":"10.1016\/j.ctarc.2026.101312_bib0025","doi-asserted-by":"crossref","first-page":"viii16","DOI":"10.1093\/annonc\/mdz384","article-title":"Identifying patients with NTRK fusion cancer","volume":"30","author":"Solomon","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101312_bib0026","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1038\/s41598-023-31055-3","article-title":"Systematic review of NTRK 1\/2\/3 fusion prevalence pan-cancer and across solid tumours","volume":"13","author":"O\u2019Haire","year":"2023","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101312_bib0027","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40265-018-1044-x","article-title":"Larotrectinib: first global approval","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101312_bib0028","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-20-2771","article-title":"FDA approval summary: entrectinib for the treatment of NTRK gene fusion Solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101312_bib0029","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.annonc.2024.07.730","article-title":"The ESMO tumour-agnostic classifier and screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development","volume":"35","author":"Westphalen","year":"2024","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101312_bib0030","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1182\/blood.V93.4.1355","article-title":"Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25)","volume":"93","author":"Eguchi","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2026.101312_bib0031","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1746-1596-6-19","article-title":"Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia","volume":"6","author":"Kralik","year":"2011","journal-title":"Diagn. Pathol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101312_bib0032","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101312_bib0033","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults","volume":"35","author":"Roberts","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101312_bib0034","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1600-0609.2011.01576.x","article-title":"Chronic eosinophilic leukaemia with ETV6-NTRK3 fusion transcript in an elderly patient affected with pancreatic carcinoma","volume":"86","author":"Forghieri","year":"2011","journal-title":"Eur. J. Haematol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101312_bib0035","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1172\/JCI120787","article-title":"Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies","volume":"128","author":"Taylor","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ctarc.2026.101312_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1146029","article-title":"NTRK fusion protein expression is absent in a large cohort of diffuse large B-cell lymphoma","volume":"13","author":"Ghandili","year":"2023","journal-title":"Front. Oncol."},{"issue":"24","key":"10.1016\/j.ctarc.2026.101312_bib0037","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood.2019003691","article-title":"Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms","volume":"135","author":"Joshi","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101312_bib0038","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/bloodadvances.2021005486","article-title":"Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways","volume":"6","author":"Witte","year":"2022","journal-title":"Blood Adv."},{"issue":"16","key":"10.1016\/j.ctarc.2026.101312_bib0039","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.3390\/cancers15164146","article-title":"RET-altered cancers-a tumor-agnostic review of biology, diagnosis and targeted therapy activity","volume":"15","author":"Desilets","year":"2023","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101312_bib0040","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s40265-024-02040-5","article-title":"RET inhibitors in RET fusion-positive lung cancers: past, present, and future","volume":"84","author":"Chen","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ctarc.2026.101312_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101911","article-title":"RET fusions in solid tumors","volume":"81","author":"Li","year":"2019","journal-title":"Cancer Treat. Rev."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101312_bib0042","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101312_bib0043","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.19.02551","article-title":"State-of-the-art strategies for targeting RET-dependent cancers","volume":"38","author":"Subbiah","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.ctarc.2026.101312_bib0044","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1158\/1078-0432.CCR-23-0459","article-title":"FDA approval summary: selpercatinib for the treatment of advanced RET fusion-positive solid tumors","volume":"29","author":"Duke","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101312_bib0045","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-019-0653-6","article-title":"Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms","volume":"25","author":"Durham","year":"2019","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101312_bib0046","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/leu.2012.109","article-title":"RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation","volume":"26","author":"Ballerini","year":"2012","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101312_bib0047","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/ng.2468","article-title":"The genetic landscape of mutations in Burkitt lymphoma","volume":"44","author":"Love","year":"2012","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101312_bib0048","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/PAI.0000000000000516","article-title":"BRAF V600E mutation across multiple tumor types: correlation between DNA-based sequencing and mutation-specific immunohistochemistry","volume":"26","author":"Loo","year":"2018","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101312_bib0049","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1158\/1535-7163.MCT-10-0799","article-title":"BRAFV600E: implications for carcinogenesis and molecular therapy","volume":"10","author":"Cantwell-Dorris","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101312_bib0050","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.trecan.2020.05.009","article-title":"Clinical development of BRAF plus MEK inhibitor combinations","volume":"6","author":"Subbiah","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ctarc.2026.101312_bib0051","doi-asserted-by":"crossref","unstructured":"Gouda M.A., Subbiah V. Expanding the benefit: dabrafenib\/Trametinib as tissue-agnostic therapy for BRAF V600E-positive adult and pediatric solid tumors. Am. Soc. Clin. Oncol. Educ. Book.. 2023;43:e404770. doi:10.1200\/EDBK_404770 PubMed PMID: 37159870.","DOI":"10.1200\/EDBK_404770"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101312_bib0052","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41571-023-00852-0","article-title":"BRAF - a tumour-agnostic drug target with lineage-specific dependencies","volume":"21","author":"Hanrahan","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.ctarc.2026.101312_bib0053","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101312_bib0054","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23319-1","article-title":"A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours","volume":"12","author":"Kang","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101312_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101312_bib0056","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1001\/jamaoncol.2020.1046","article-title":"Outcomes following immune checkpoint inhibitor treatment of patients with microsatellite instability-high cancers: a systematic review and meta-analysis","volume":"6","author":"Petrelli","year":"2020","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101312_bib0057","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s00262-025-03980-x","article-title":"Microsatellite instability-high status as a pan-cancer biomarker for immunotherapy efficacy","volume":"74","author":"Landre","year":"2025","journal-title":"Cancer Immunol. Immunther."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101312_bib0058","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3390\/biom12081031","article-title":"Dostarlimab: a review","volume":"12","author":"Costa","year":"2022","journal-title":"Biomolecules"},{"issue":"14","key":"10.1016\/j.ctarc.2026.101312_bib0059","doi-asserted-by":"crossref","first-page":"7839","DOI":"10.3390\/ijms23147839","article-title":"The multi-dimensional biomarker landscape in cancer immunotherapy","volume":"23","author":"Lee","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101312_bib0060","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jmoldx.2019.06.011","article-title":"A novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability-high cases in 67,000 patient samples","volume":"21","author":"Trabucco","year":"2019","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.ctarc.2026.101312_bib0061","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1200\/PO.20.00185","article-title":"Clinical pan-cancer assessment of mismatch repair deficiency using tumor-only, targeted next-generation sequencing","volume":"4","author":"Albayrak","year":"2020","journal-title":"JCO Precis. Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101312_bib0062","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1002\/cam4.2870","article-title":"Microsatellite instability and its associations with the clinicopathologic characteristics of diffuse large B-cell lymphoma","volume":"9","author":"Tian","year":"2020","journal-title":"Cancer Med."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101312_bib0063","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3109\/10428194.2012.739687","article-title":"Mutation mismatch repair gene deletions in diffuse large B-cell lymphoma","volume":"54","author":"Couronn\u00e9","year":"2013","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101312_bib0064","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a006318","article-title":"PD-L1+ diffuse large B-cell lymphoma with extremely high mutational burden and microsatellite instability due to acquired PMS2 mutation","volume":"9","author":"Allbee","year":"2023","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101312_bib0065","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3109\/10428194.2012.723211","article-title":"Analysis of microsatellite instability in gastric mucosa-associated lymphoid tissue lymphoma","volume":"54","author":"Degroote","year":"2013","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101312_bib0066","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.annonc.2024.03.007","article-title":"Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities","volume":"35","author":"Wang","year":"2024","journal-title":"Ann. Oncol."},{"issue":"24","key":"10.1016\/j.ctarc.2026.101312_bib0067","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.3390\/cancers15245841","article-title":"Challenges and future directions in the management of tumor mutational burden-high (TMB-H) advanced solid malignancies","volume":"15","author":"Ahmed","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101312_bib0068","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101312_bib0069","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23319-1","article-title":"A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours","volume":"12","author":"Kang","year":"2022","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101312_bib0070","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101312_bib0071","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101312_bib0072","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"10.1016\/j.ctarc.2026.101312_bib0073","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241273053","article-title":"Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies","volume":"16","author":"Jeong","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101312_bib0074","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3390\/cancers13020214","article-title":"Immune-checkpoint inhibitors in B-cell lymphoma","volume":"13","author":"Armengol","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101312_bib0075","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/cac2.12587","article-title":"Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies","volume":"44","author":"Sun","year":"2024","journal-title":"Cancer Commun"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101312_bib0076","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clml.2023.09.002","article-title":"Efficacy and safety of immune checkpoint inhibitors in hematologic malignancies","volume":"24","author":"Bilgihan","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"27","key":"10.1016\/j.ctarc.2026.101312_bib0077","doi-asserted-by":"crossref","first-page":"44960","DOI":"10.18632\/oncotarget.16680","article-title":"Mechanisms of PD-1\/PD-L1 expression and prognostic relevance in non-hodgkin lymphoma: a summary of immunohistochemical studies","volume":"8","author":"Gravelle","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101312_bib0078","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00277-022-04760-8","article-title":"Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia-lymphoma","volume":"101","author":"Onishi","year":"2022","journal-title":"Ann. Hematol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101312_bib0079","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7195","article-title":"Expression and prognostic significance of the PD-1\/PD-L1 pathway in AIDS-related non-hodgkin lymphoma","volume":"13","author":"Zhao","year":"2024","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101312_bib0080","doi-asserted-by":"crossref","first-page":"6726","DOI":"10.1038\/s41467-021-26974-6","article-title":"Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma","volume":"12","author":"Phillips","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2026.101312_bib0081","unstructured":"Research C for DE and. Pembrolizumab (KEYTRUDA) for classical Hodgkin lymphoma. FDA [Internet]. 2019 Feb 9 [cited 2025 Jun 22]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/pembrolizumab-keytruda-classical-hodgkin-lymphoma."},{"key":"10.1016\/j.ctarc.2026.101312_bib0082","unstructured":"Research C for DE and. FDA approves pembrolizumab for treatment of relapsed or refractory PMBCL. FDA [Internet]. 2024 Aug 9 [cited 2025 Jun 22]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-treatment-relapsed-or-refractory-pmbcl."},{"key":"10.1016\/j.ctarc.2026.101312_bib0083","unstructured":"Research C for DE and. Nivolumab (Opdivo) for Hodgkin Lymphoma. FDA [Internet]. 2019 Feb 9 [cited 2025 Jun 22]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/nivolumab-opdivo-hodgkin-lymphoma."},{"key":"10.1016\/j.ctarc.2026.101312_bib0084","unstructured":"Research C for DE and. Nivolumab (Opdivo) for Hodgkin Lymphoma. FDA [Internet]. 2019 Feb 9 [cited 2025 Jun 22]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/nivolumab-opdivo-hodgkin-lymphoma."},{"key":"10.1016\/j.ctarc.2026.101312_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101636","article-title":"A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-hodgkin lymphoma; a friend or foe?","volume":"30","author":"Davoodi-Moghaddam","year":"2023","journal-title":"Transl. Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101312_bib0086","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrclinonc.2012.156","article-title":"From drug discovery to biomarker-driven clinical trials in lymphoma","volume":"9","author":"Younes","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101312_bib0087","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1038\/s41375-020-1000-0","article-title":"Whole-genome sequencing identifies responders to Pembrolizumab in relapse\/refractory natural-killer\/T cell lymphoma","volume":"34","author":"Lim","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101312_bib0088","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/14737140.2023.2192930","article-title":"Pemigatinib for the treatment of myeloid\/lymphoid neoplasms with FGFR1 rearrangement","volume":"23","author":"Freyer","year":"2023","journal-title":"Expert Rev. AntiCancer Ther."},{"issue":"17","key":"10.1016\/j.ctarc.2026.101312_bib0089","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.4155\/fmc-2018-0103","article-title":"Recent developments and advances of FGFR as a potential target in cancer","volume":"10","author":"Xue","year":"2018","journal-title":"Future Med. Chem."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101312_bib0090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-024-01558-1","article-title":"Targeting FGFR for cancer therapy","volume":"17","author":"Zhang","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101312_bib0091","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s10495-013-0886-7","article-title":"Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers","volume":"18","author":"Tiong","year":"2013","journal-title":"Apoptosis"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101312_bib0092","first-page":"433","article-title":"The evolving landscape of tissue-agnostic therapies in precision oncology","volume":"74","author":"Subbiah","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101312_bib0093","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s40265-020-01330-y","article-title":"Pemigatinib: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"issue":"20","key":"10.1016\/j.ctarc.2026.101312_bib0094","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.21037\/atm-20-5118","article-title":"A comprehensive pan-cancer study of fibroblast growth factor receptor aberrations in Chinese cancer patients","volume":"8","author":"Sun","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ctarc.2026.101312_bib0095","article-title":"Mutational profile and clonal evolution of relapsed\/refractory diffuse large B-cell lymphoma","volume":"11","author":"Lee","year":"2021","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101312_bib0096","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1182\/bloodadvances.2024014928","article-title":"Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma with novel FGFR1 fusion treated with pemigatinib","volume":"9","author":"Torres-Cabala","year":"2025","journal-title":"Blood Adv."},{"issue":"19","key":"10.1016\/j.ctarc.2026.101312_bib0097","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1182\/blood.2025031016","article-title":"Myeloid\/lymphoid neoplasms with FGFR1 rearrangement and pemigatinib","volume":"147","author":"Vannucchi","year":"2026","journal-title":"Blood"},{"issue":"42","key":"10.1016\/j.ctarc.2026.101312_bib0098","doi-asserted-by":"crossref","first-page":"69060","DOI":"10.18632\/oncotarget.11264","article-title":"HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives","volume":"7","author":"Fanotto","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101312_bib0099","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s11523-024-01079-4","article-title":"Trastuzumab-Deruxtecan: redefining HER2 as a tumor agnostic biomarker","volume":"19","author":"Zouein","year":"2024","journal-title":"Target. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101312_bib0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies - a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101312_bib0101","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119307","article-title":"A pan-cancer analysis of the HER family gene and their association with prognosis, tumor microenvironment, and therapeutic targets","volume":"273","author":"Yang","year":"2021","journal-title":"Life Sci."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101312_bib0102","doi-asserted-by":"crossref","first-page":"574","DOI":"10.5858\/2002-126-0574-LOHNEI","article-title":"Lack of HER-2\/neu expression in Hodgkin and non-hodgkin lymphoma","volume":"126","author":"Bairey","year":"2002","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"5B","key":"10.1016\/j.ctarc.2026.101312_bib0103","first-page":"3233","article-title":"Lack of HER-2\/neu overexpression in non-Hodgkin\u2019s lymphoma","volume":"24","author":"L\u00fcftner","year":"2004","journal-title":"Anticancer Res."},{"issue":"20","key":"10.1016\/j.ctarc.2026.101312_bib0104","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.3390\/cancers13205038","article-title":"Neuregulin 1 gene (NRG1). A potentially new targetable alteration for the treatment of lung cancer","volume":"13","author":"Rosas","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101312_bib0105","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1093\/nar\/gkw282","article-title":"Discovering and understanding oncogenic gene fusions through data intensive computational approaches","volume":"44","author":"Latysheva","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"16","key":"10.1016\/j.ctarc.2026.101312_bib0106","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1158\/1078-0432.CCR-19-0160","article-title":"Detection of NRG1 gene fusions in solid tumors","volume":"25","author":"Jonna","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101312_bib0107","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.annonc.2020.08.2335","article-title":"NRG1 fusion-driven tumors: biology, detection and the therapeutic role of afatinib and other ErbB-targeting agents","volume":"31","author":"Laskin","year":"2020","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101312_bib0108","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.21037\/tcr.2019.11.02","article-title":"Invasive mucinous adenocarcinoma of the lung","volume":"8","author":"Xu","year":"2019","journal-title":"Transl. Cancer Res."},{"issue":"14","key":"10.1016\/j.ctarc.2026.101312_bib0109","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1158\/1078-0432.CCR-21-0423","article-title":"Comprehensive molecular and clinicopathologic analysis of 200 pulmonary invasive mucinous adenocarcinomas identifies distinct characteristics of molecular subtypes","volume":"27","author":"Chang","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101312_bib0110","doi-asserted-by":"crossref","first-page":"9661","DOI":"10.18632\/oncotarget.23800","article-title":"Frequent NRG1 fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression","volume":"9","author":"Trombetta","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctarc.2026.101312_bib0111","first-page":"143","article-title":"NRG1 fusions in NSCLC: being eNRGy conscious","volume":"Volume 15","author":"Gupta","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101312_bib0112","doi-asserted-by":"crossref","first-page":"9081","DOI":"10.1200\/JCO.2019.37.15_suppl.9081","article-title":"NRG1 fusion-positive lung cancers: clinicopathologic profile and treatment outcomes from a global multicenter registry","volume":"37","author":"Duruisseaux","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.ctarc.2026.101312_bib0113","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1158\/1078-0432.CCR-19-1280","article-title":"Oncogenic NRG1 fusions: a new hope for targeted therapy in pancreatic cancer","volume":"25","author":"Aguirre","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101312_bib0114","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1158\/2159-8290.CD-17-1004","article-title":"Response to ERBB3-directed targeted therapy in NRG1-rearranged cancers","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101312_bib0115","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s11912-025-01640-y","article-title":"NRG1 Fusions: the new kid on the block","volume":"27","author":"Gupta","year":"2025","journal-title":"Curr. Oncol. Rep."},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2026.101312_bib0116","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1200\/JCO.2019.37.15_suppl.3129","article-title":"Clinicopathologic characteristics of NRG1 fusion-positive cancers: a single-institution study","volume":"37","author":"Schram","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"6278","key":"10.1016\/j.ctarc.2026.101312_bib0117","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ctarc.2026.101312_bib0118","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102264","article-title":"TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers","volume":"52","author":"Briggs","year":"2025","journal-title":"Transl. Oncol."},{"issue":"22","key":"10.1016\/j.ctarc.2026.101312_bib0119","first-page":"6639","article-title":"Methylthioadenosine phosphorylase, a gene frequently codeleted with p16cdkN2a\/ARF, acts as a tumor suppressor in a breast cancer cell Line1","volume":"62","author":"Christopher","year":"2002","journal-title":"Cancer Res."},{"issue":"14","key":"10.1016\/j.ctarc.2026.101312_bib0120","doi-asserted-by":"crossref","first-page":"5961","DOI":"10.1158\/0008-5472.CAN-09-0145","article-title":"Mice heterozygous for germ-line mutations in methylthioadenosine phosphorylase (MTAP) die prematurely of T-cell lymphoma","volume":"69","author":"Kadariya","year":"2009","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101312_bib0121","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101312_bib0122","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1038\/s41467-021-25894-9","article-title":"9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy","volume":"12","author":"Han","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2026.101312_bib0123","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102264","article-title":"TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers","volume":"52","author":"Briggs","year":"2025","journal-title":"Transl. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101312_bib0124","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3390\/cells9020492","article-title":"Loss of 5\u2019-methylthioadenosine phosphorylase (MTAP) is frequent in high-grade gliomas; nevertheless, it is not associated with higher tumor aggressiveness","volume":"9","author":"Menezes","year":"2020","journal-title":"Cells"},{"issue":"13","key":"10.1016\/j.ctarc.2026.101312_bib0125","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1158\/0008-5472.CAN-18-1010","article-title":"MTAP loss promotes stemness in glioblastoma and confers unique susceptibility to purine starvation","volume":"79","author":"Hansen","year":"2019","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101312_bib0126","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1097\/PAS.0000000000002297","article-title":"Prevalence of S-methyl-5\u2032-thioadenosine phosphorylase (MTAP) deficiency in human cancer","volume":"48","author":"Gorbokon","year":"2024","journal-title":"Am. J. Surg. Pathol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101312_bib0127","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/oncolo\/oyae011","article-title":"Methylthioadenosine phosphorylase genomic loss in advanced gastrointestinal cancers","volume":"29","author":"Ngoi","year":"2024","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101312_bib0128","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.jid.2016.01.028","article-title":"Independent loss of methylthioadenosine phosphorylase (MTAP) in primary cutaneous T-cell lymphoma","volume":"136","author":"Woollard","year":"2016","journal-title":"J. Invest. Dermatol."},{"issue":"9_Supplement","key":"10.1016\/j.ctarc.2026.101312_bib0129","first-page":"1156","article-title":"MTAP gene deletions in mantle cell lymphoma are associated with lack of protein expression and shorter survival","volume":"65","author":"Balague","year":"2005","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101312_bib0130","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1021\/acs.jmedchem.4c03067","article-title":"Discovery of TNG462: a highly potent and selective MTA-cooperative PRMT5 inhibitor to target cancers with MTAP deletion","volume":"68","author":"Cottrell","year":"2025","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101312_bib0131","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2020.12.010","article-title":"MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage","volume":"39","author":"Kalev","year":"2021","journal-title":"Cancer Cell"},{"issue":"13_Supplement","key":"10.1016\/j.ctarc.2026.101312_bib0132","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1158\/1538-7445.AM2019-2714","article-title":"Abstract 2714: targeting MAT2A in CDKN2A\/MTAP-deleted cancers","volume":"79","author":"Marjon","year":"2019","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101312_bib0133","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41698-023-00449-x","article-title":"ALK fusions in the pan-cancer setting: another tumor-agnostic target?","volume":"7","author":"Shreenivas","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.ctarc.2026.101312_bib0134","unstructured":"ALK in cancer: from function to therapeutic targeting | nature reviews cancer [Internet]. [cited 2025 Jul 6]. Available from: https:\/\/www.nature.com\/articles\/s41568-025-00797-9."},{"key":"10.1016\/j.ctarc.2026.101312_bib0135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41698-023-00449-x","article-title":"ALK fusions in the pan-cancer setting: another tumor-agnostic target?","volume":"7","author":"Shreenivas","year":"2023","journal-title":"NPJ Precis. Oncol."},{"issue":"28","key":"10.1016\/j.ctarc.2026.101312_bib0136","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","article-title":"Targeting ALK with Crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a children\u2019s oncology group study","volume":"35","author":"Moss\u00e9","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101312_bib0137","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1111\/cas.14671","article-title":"Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: an open-label phase II trial","volume":"111","author":"Fukano","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ctarc.2026.101312_bib0138","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112984","article-title":"Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcS\u00e9-crizotinib trial","volume":"191","author":"Brugi\u00e8res","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101312_bib0139","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3390\/cancers17030428","article-title":"The role of KRAS mutations in colorectal cancer: biological insights, clinical implications, and future therapeutic perspectives","volume":"17","author":"Takeda","year":"2025","journal-title":"Cancers"},{"issue":"25","key":"10.1016\/j.ctarc.2026.101312_bib0140","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101312_bib0141","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","article-title":"FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC","volume":"28","author":"Nakajima","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101312_bib0142","unstructured":"Adagrasib in non\u2013Small-cell lung cancer harboring a KRASG12C mutation | New England Journal of Medicine [Internet]. [cited 2025 Jul 6]. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2204619."},{"key":"10.1016\/j.ctarc.2026.101312_bib0143","unstructured":"From bench to bedside: current development and emerging trend of KRAS-targeted therapy | Acta Pharmacologica Sinica [Internet]. [cited 2025 Jul 6]. Available from: https:\/\/www.nature.com\/articles\/s41401-023-01194-4."},{"key":"10.1016\/j.ctarc.2026.101312_bib0144","doi-asserted-by":"crossref","unstructured":"KRAS and RAS-MAPK pathway deregulation in mature B cell lymphoproliferative disorders [Internet]. [cited 2025 Jul 6]. Available from: https:\/\/www.mdpi.com\/2072-6694\/14\/3\/666.","DOI":"10.3390\/cancers14030666"},{"key":"10.1016\/j.ctarc.2026.101312_bib0145","unstructured":"P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC\/BCL2 expression in diffuse large B-cell lymphoma | Modern Pathology [Internet]. [cited 2025 Jul 6]. Available from: https:\/\/www.nature.com\/articles\/modpathol2016178."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101312_bib0146","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","article-title":"Drugging p53 in cancer: one protein, many targets","volume":"22","author":"Hassin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101312_bib0147","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","article-title":"Targeting mutant p53 for cancer therapy: direct and indirect strategies","volume":"14","author":"Hu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101312_bib0148","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/humu.23035","article-title":"TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data","volume":"37","author":"Bouaoun","year":"2016","journal-title":"Hum. Mutat."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101312_bib0149","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/oncolo\/oyab053","article-title":"Homologous recombination deficiency: concepts, definitions, and assays","volume":"27","author":"Stewart","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2026.101312_bib0150","doi-asserted-by":"crossref","unstructured":"Homologous recombination deficiency (HRD) and BRCA 1\/2 gene mutation for predicting the effect of platinum-based neoadjuvant chemotherapy of early-stage triple-negative breast cancer (TNBC): a systematic review and meta-analysis [Internet]. [cited 2025 Jul 12]. Available from: https:\/\/www.mdpi.com\/2075-4426\/12\/2\/323.","DOI":"10.3390\/jpm12020323"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101312_bib0151","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/curroncol32020090","article-title":"Causative genes of homologous recombination deficiency (HRD)-related breast cancer and specific strategies at present","volume":"32","author":"Nakamura","year":"2025","journal-title":"Curr. Oncol."},{"issue":"PO.17","key":"10.1016\/j.ctarc.2026.101312_bib0152","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00286","article-title":"Prevalence of homologous recombination-related gene mutations across multiple cancer types","volume":"2018","author":"Heeke","year":"2018","journal-title":"JCo Precis. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101312_bib0153","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","article-title":"Pan-cancer landscape of homologous recombination deficiency","volume":"11","author":"Nguyen","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101312_bib0154","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3390\/ijms23010348","article-title":"Homologous recombination deficiencies and hereditary tumors","volume":"23","author":"Yamamoto","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"29","key":"10.1016\/j.ctarc.2026.101312_bib0155","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1073\/pnas.1706392114","article-title":"ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair","volume":"114","author":"Chen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ctarc.2026.101312_bib0156","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1307839","article-title":"Targeting the DNA damage response in hematological malignancies","volume":"14","author":"De Mel","year":"2024","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101312_bib0157","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","article-title":"ATM mutations in cancer: therapeutic implications","volume":"15","author":"Choi","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101312_bib0158","doi-asserted-by":"crossref","first-page":"463","DOI":"10.5732\/cjc.011.10111","article-title":"PARP inhibitors: its role in treatment of cancer","volume":"30","author":"Chen","year":"2011","journal-title":"Chin. J. Cancer"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101312_bib0159","doi-asserted-by":"crossref","first-page":"405","DOI":"10.32604\/or.2023.028310","article-title":"Targeting DNA repair for cancer treatment: lessons from PARP inhibitor trials","volume":"31","author":"Nambiar","year":"2023","journal-title":"Oncol. Res."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101312_bib0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100049","article-title":"Homologous recombination repair deficiency: an overview for pathologists","volume":"36","author":"Doig","year":"2023","journal-title":"Mod. Pathol."},{"issue":"19","key":"10.1016\/j.ctarc.2026.101312_bib0161","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.3390\/cancers14194621","article-title":"Targeting homologous recombination deficiency in ovarian cancer with PARP inhibitors: synthetic lethal strategies that impact overall survival","volume":"14","author":"Xie","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101312_bib0162","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1002\/onco.13551","article-title":"FDA approval summary: olaparib monotherapy or in combination with Bevacizumab for the maintenance treatment of patients with advanced ovarian cancer","volume":"26","author":"Arora","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2026.101312_bib0163","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1159557","article-title":"PARP inhibitors in metastatic prostate cancer","volume":"13","author":"Taylor","year":"2023","journal-title":"Front. Oncol."},{"issue":"18","key":"10.1016\/j.ctarc.2026.101312_bib0164","doi-asserted-by":"crossref","first-page":"6524","DOI":"10.3390\/molecules28186524","article-title":"Development and comparative evaluation of two different label-free and sensitive fluorescence platforms for analysis of Olaparib: a recently FDA-approved drug for the treatment of ovarian and breast cancer","volume":"28","author":"Darwish","year":"2023","journal-title":"Molecules"},{"issue":"23","key":"10.1016\/j.ctarc.2026.101312_bib0165","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.1158\/1078-0432.CCR-17-1337","article-title":"FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer","volume":"23","author":"Balasubramaniam","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101312_bib0166","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/onco.13585","article-title":"FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA-mutated metastatic castrate-resistant prostate cancer","volume":"26","author":"Anscher","year":"2021","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101312_bib0167","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3390\/ph16091261","article-title":"Niraparib and advanced ovarian cancer: a beacon in the Non-BRCA mutated setting","volume":"16","author":"Maiorano","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101312_bib0168","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ccell.2019.07.007","article-title":"LMO2 Confers synthetic lethality to PARP inhibition in DLBCL","volume":"36","author":"Parvin","year":"2019","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101312_bib0169","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/emmm.201200229","article-title":"Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53","volume":"4","author":"Williamson","year":"2012","journal-title":"EMBO Mol. Med."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101312_bib0170","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1038\/s41375-025-02688-2","article-title":"Integration of [18F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma","volume":"39","author":"Dondolin","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2026.101312_bib0171","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz244","article-title":"METEOR-1: a phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours","volume":"30","author":"Siu","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101312_bib0172","unstructured":"Janssen Research & Development, LLC. A phase 1, first-in-Human, open-label study of the safety, pharmacokinetics, and pharmacodynamics of JNJ-64619178, an inhibitor of protein arginine methyltransferase 5 (PRMT5) in subjects with advanced cancers [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Jul [cited 2025 Jul 28]. Clinical trial registration no.: NCT03573310. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03573310."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101312_bib0173","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/ajh.25043","article-title":"Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): a phase 1b open-label study","volume":"93","author":"Gambacorti-Passerini","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ctarc.2026.101312_bib0174","unstructured":"Peter MacCallum Cancer Centre, Australia. An open label, signal seeking, translational, phase II trial of Pamiparib in combination with Tislelizumab in patients with advanced tumours with homologous recombination repair defects [Clinical trial registration] [Internet]. clinicaltrials.gov; 2023 Mar [cited 2025 Jul 28]. Clinical trial registration no.: NCT04985721. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04985721."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101312_bib0175","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101312_bib0176","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101312_bib0177","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejca.2023.02.016","article-title":"Pembrolizumab for previously treated, microsatellite instability\u2013high\/mismatch repair\u2013deficient advanced colorectal cancer: final analysis of KEYNOTE-164","volume":"186","author":"Le","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101312_bib0178","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s43018-024-00894-y","article-title":"Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial","volume":"6","author":"Marabelle","year":"2025","journal-title":"Nat. Cancer"},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2026.101312_bib0179","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.10040","article-title":"Pembrolizumab in pediatric participants with relapsed or refractory microsatellite instability-high solid tumors: results from the phase 1\/2 KEYNOTE-051 trial","volume":"43","author":"Pappo","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.ctarc.2026.101312_bib0180","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125514s132lbl.pdf [Internet]. [cited 2025 Jun 12]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125514s132lbl.pdf."},{"key":"10.1016\/j.ctarc.2026.101312_bib0181","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejca.2023.02.016","article-title":"Pembrolizumab for previously treated, microsatellite instability-high\/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164","volume":"186","author":"Le","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101312_bib0182","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(19)30671-0","article-title":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101312_bib0183","unstructured":"Pembrolizumab in pediatric participants with relapsed or refractory microsatellite instability-high solid tumors: results from the phase 1\/2 KEYNOTE-051 trial. | Journal of Clinical Oncology [Internet]. [cited 2025 Jul 20]. Available from: https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2025.43.16_suppl.10040."},{"key":"10.1016\/j.ctarc.2026.101312_bib0184","unstructured":"Research C for DE and. FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors. FDA [Internet]. 2024 Aug 9 [cited 2025 Jun 13]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors."},{"key":"10.1016\/j.ctarc.2026.101312_bib0185","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761174s009lbl.pdf [Internet]. [cited 2025 Jun 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761174s009lbl.pdf."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101312_bib0186","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor activity and safety of Dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial","volume":"6","author":"Andr\u00e9","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ctarc.2026.101312_bib0187","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/210861s012lbl.pdf [Internet]. [cited 2025 Jun 12]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/210861s012lbl.pdf."},{"key":"10.1016\/j.ctarc.2026.101312_bib0188","unstructured":"Efficacy and safety of larotrectinib in patients with non-primary central nervous system TRK fusion cancer: an updated analysis. | Journal of Clinical Oncology [Internet]. [cited 2025 Jul 20]. Available from: https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2025.43.16_suppl.3148."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101312_bib0189","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101312_bib0190","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212725s000lbl.pdf [Internet]. [cited 2025 Jun 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212725s000lbl.pdf."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101312_bib0191","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of Entrectinib in patients with NTRK fusion-positive solid tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101312_bib0192","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218213s001lbl.pdf [Internet]. [cited 2025 Jun 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218213s001lbl.pdf."},{"key":"10.1016\/j.ctarc.2026.101312_bib0193","doi-asserted-by":"crossref","first-page":"S787","DOI":"10.1016\/j.annonc.2023.09.2405","article-title":"1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: update from the phase I\/II TRIDENT-1 trial","volume":"34","author":"Solomon","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101312_bib0194","unstructured":"Research C for DE and. FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation. FDA [Internet]. 2024 Aug 9 [cited 2025 Jun 13]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid."},{"key":"10.1016\/j.ctarc.2026.101312_bib0195","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/202806s038,217514s009lbl.pdf [Internet]. [cited 2025 Jun 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/202806s038,217514s009lbl.pdf."},{"issue":"Supplement 1","key":"10.1016\/j.ctarc.2026.101312_bib0196","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood-2021-148103","article-title":"A phase 2 study of Pemigatinib (FIGHT-203; INCB054828) in patients with myeloid\/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement (MLN FGFR1)","volume":"138","author":"Gotlib","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2026.101312_bib0197","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213736s002lbl.pdf [Internet]. [cited 2025 Jun 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213736s002lbl.pdf."},{"key":"10.1016\/j.ctarc.2026.101312_bib0198","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1016\/S2152-2650(24)01430-7","article-title":"MPN-384 A phase 2 study of Pemigatinib (FIGHT-203; INCB054828) in patients with myeloid\/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) gene rearrangement","volume":"24","author":"Vannucchi","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ctarc.2026.101312_bib0199","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/213246s011s013lbl.pdf [Internet]. [cited 2025 Jun 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/213246s011s013lbl.pdf."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101312_bib0200","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101312_bib0201","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab Deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101312_bib0202","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101312_bib0203","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:54:50Z","timestamp":1790913290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226002236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":203,"alternative-id":["S2468294226002236"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101312","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing tumor-agnostic biomarkers for precision medicine in lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101312","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101312"}}